# OrphanCure Full Pipeline Report: repodb_074e03e7fac6728e

- Drug: Irinotecan
- Disease: signet ring adenocarcinoma of the rectum
- Mode: no_target_expansion
- Status: completed
- Final assessment: Unlikely

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Unlikely",
      "confidence": "Low",
      "summary": "No literature was retrieved to support or refute the repurposing of Irinotecan for rectal signet ring cell adenocarcinoma. Therefore, based on the current data, this repurposing is unlikely.",
      "evidence_counts": {
        "total_papers": 0,
        "supporting": 0,
        "contradicting": 0,
        "inconclusive": 0
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose IRINOTECAN for rectal signet ring cell adenocarcinoma",
      "drug": {
        "id": "CHEMBL481",
        "name": "IRINOTECAN",
        "aliases": [
          "CPT-11",
          "Camptosar",
          "Irinotecan hydrochloride",
          "Onivyde",
          "Topoisomerase 1 inhibitor"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "MONDO_0004336",
        "name": "rectal signet ring cell adenocarcinoma",
        "aliases": [
          "Signet ring cell adenocarcinoma of rectum",
          "Rectal SRC adenocarcinoma",
          "Adenocarcinoma, signet ring cell, of rectum",
          "Rectal signet ring carcinoma",
          "Signet ring cell carcinoma of the rectum"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 0,
      "polarity": {
        "supports": 0,
        "contradicts": 0,
        "inconclusive": 0
      },
      "support_ratio": "No papers retrieved",
      "queries_used": 10,
      "top_papers": []
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Low",
      "dimensions": {
        "mechanistic_strength": "Low",
        "literature_strength": "Low",
        "clinical_evidence": "Low"
      },
      "quality_scorecard": {
        "overall_score": 0.388,
        "decision": "rerun",
        "dimensions": {
          "completeness": {
            "score": 0.8,
            "reason": "4/5 sections present"
          },
          "evidence_support": {
            "score": 0.0,
            "reason": "No claims generated"
          },
          "citation_validity": {
            "score": 0.0,
            "reason": "0 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/0 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 0.0,
            "reason": "0/0 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "evidence_support",
          "citation_validity",
          "mechanistic_specificity",
          "contradiction_handling",
          "traceability"
        ],
        "rerun_targets": [
          "LiteratureAgent",
          "MechanismAgent",
          "SynthesisCriticAgent"
        ]
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Potential for off-target effects or toxicity without specific rationale.",
        "Lack of supporting evidence."
      ],
      "limitations": [
        "The analysis is limited by the absence of any retrieved literature.",
        "No mechanistic data was provided to support the hypothesis."
      ],
      "missing_data": [
        "Studies on Irinotecan efficacy in rectal signet ring cell adenocarcinoma.",
        "Mechanistic studies linking Irinotecan to signet ring cell adenocarcinoma.",
        "Clinical trial data for Irinotecan in this specific indication."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Conduct a thorough literature search using broader keywords and databases.",
        "Investigate the known mechanisms of Irinotecan and signet ring cell adenocarcinoma to identify potential molecular links.",
        "If potential links are found, consider in vitro or in vivo studies to evaluate efficacy."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 0,
      "claims": []
    },
    "11_provenance_appendix": {
      "total_entries": 0,
      "entries": []
    }
  },
  "metadata": {
    "run_id": "592b668882bd",
    "created_at": "2026-06-03T12:18:48.707632+00:00",
    "drug": "IRINOTECAN",
    "disease": "rectal signet ring cell adenocarcinoma",
    "total_claims": 0,
    "quality_score": 0.3875,
    "reruns": 2
  }
}
```
